Efficacy of Symbicort pMDI administered once daily in adolescents and adults during 12 weeks - STEM
Study identifier:SD-039-0726
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A 12 week, Randomized, Double-Blind, Double-Dummy, Placebo and Active-controlled Study of Symbicort pMDI Administered once daily in Adults and Adolescents with Asthma - STEM
Medical condition
asthma
Phase
Phase 3
Healthy volunteers
No
Study drug
budesonide/formoterol, budesonide and placebo
Sex
All
Actual Enrollment
750
Study type
Interventional
Age
16 Years +
Date
Study Start Date: 01 Apr 2003
Primary Completion Date: -
Study Completion Date: 01 Jun 2004
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | - |
| Placebo Comparator: 2 | - |
Contacts
Investigators
Principal Investigator
Catherine Bonuccelli
AstraZeneca
